title: Accumulation of MRI contrast agents in malignant fibrous histiocytoma for gadolinium neutron capture therapy.
abstract: Neutron-capture therapy with gadolinium (Gd-NCT) has therapeutic potential, especially that gadolinium is generally used as a contrast medium in magnetic resonance imaging (MRI). The accumulation of gadolinium in a human sarcoma cell line, malignant fibrosis histiocytoma (MFH) Nara-H, was visualized by the MRI system. The commercially available MRI contrast medium Gd-DTPA (Magnevist, dimeglumine gadopentetate aqueous solution) and the biodegradable and highly gadopentetic acid (Gd-DTPA)-loaded chitosan nanoparticles (Gd-nanoCPs) were prepared as MRI contrast agents. The MFH cells were cultured and collected into three falcon tubes that were set into the 3-tesra MRI system to acquire signal intensities from each pellet by the spin echo method, and the longitudinal relaxation time (T1) was calculated. The amount of Gd in the sample was measured by inductively coupled plasma atomic emission spectrography (ICP-AES). The accumulation of gadolinium in cells treated with Gd-nanoCPs was larger than that in cells treated with Gd-DTPA. In contrast, and compared with the control, Gd-DTPA was more effective than Gd-nanoCPs in reducing T1, suggesting that the larger accumulation exerted the adverse effect of lowering the enhancement of MRI. Further studies are warranted to gain insight into the therapeutic potential of Gd-NCT.
authors.affiliation: Department of Orthopaedic Surgery, Hyogo Cancer Center, Akashi 673-0021, Japan. fujitaku@hp.pref.hyogo.jp
authors.forename: T
authors.initials: T
authors.lastname: Fujimoto
authors.forename: H
authors.initials: H
authors.lastname: Ichikawa
authors.forename: T
authors.initials: T
authors.lastname: Akisue
authors.forename: I
authors.initials: I
authors.lastname: Fujita
authors.forename: K
authors.initials: K
authors.lastname: Kishimoto
authors.forename: H
authors.initials: H
authors.lastname: Hara
authors.forename: M
authors.initials: M
authors.lastname: Imabori
authors.forename: H
authors.initials: H
authors.lastname: Kawamitsu
authors.forename: P
authors.initials: P
authors.lastname: Sharma
authors.forename: S C
authors.initials: SC
authors.lastname: Brown
authors.forename: B M
authors.initials: BM
authors.lastname: Moudgil
authors.forename: M
authors.initials: M
authors.lastname: Fujii
authors.forename: T
authors.initials: T
authors.lastname: Yamamoto
authors.forename: M
authors.initials: M
authors.lastname: Kurosaka
authors.forename: Y
authors.initials: Y
authors.lastname: Fukumori
mesh_terms: D045744:Cell Line, Tumor; D048271:Chitosan; D003287:Contrast Media / Q000493:pharmacokinetics; D005682:Gadolinium / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019786:Gadolinium DTPA; D051677:Histiocytoma, Malignant Fibrous / Q000175:diagnosis* / Q000378:metabolism / Q000532:radiotherapy*; D006801:Humans; D008279:Magnetic Resonance Imaging; D053768:Metal Nanoparticles; D017247:Neutron Capture Therapy / Q000379:methods*; D019047:Phantoms, Imaging
chemical_list: D003287:Contrast Media; D048271:Chitosan; D005682:Gadolinium; D019786:Gadolinium DTPA